These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23490378)

  • 41. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.
    Lal BB; Sood V; Khanna R; Rawat D; Verma S; Alam S
    Indian J Gastroenterol; 2018 Jul; 37(4):326-334. PubMed ID: 30168073
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.
    Al Ashgar H; Peedikayil MC; Al Quaiz M; Al Sohaibani F; Al Fadda A; Khan MQ; Thoralsson E; Al Thawadi S; Al Jedai A; Al Kahtani K
    Saudi J Gastroenterol; 2017; 23(3):190-198. PubMed ID: 28611343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk.
    Xiong F; Bao X; Gu N; Guo J; Wang J; Ma Y; Yu L; Gao Y; Tan B; Lu J
    Infect Genet Evol; 2020 Mar; 78():104101. PubMed ID: 31689542
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients.
    Yu XQ; Wang MJ; Yu DM; Chen PZ; Zhu MY; Huang W; Han Y; Gong QM; Zhang XX
    J Clin Microbiol; 2020 Aug; 58(9):. PubMed ID: 32554476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.
    Hagiwara S; Nishida N; Watanabe T; Ida H; Sakurai T; Ueshima K; Takita M; Komeda Y; Nishijima N; Osaki Y; Kudo M
    Antivir Ther; 2018; 23(6):513-521. PubMed ID: 29438098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
    Lu HY; Zhuang LW; Yu YY; Si CW
    J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
    Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
    Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
    Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
    Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.
    Boglione L; Cardellino CS; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2014 Nov; 86(11):1845-50. PubMed ID: 25131947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.